Peter C. Adamson, MD
Chief, Division of Clinical Pharmacology and Therapeutics
Director, Experimental Therapeutics in Oncology
Professor of Pediatrics, University of Pennsylvania School of Medicine
Resume
- Department: Pediatrics
- Division: Clinical Pharmacology
- Primary Address:
Chair, Children's Oncology Group
Chief, Division of Clinical Pharmacology & Therapeutics
The Children's Hospital of Philadelphia
CTRB 10060
3501 Civic Center Blvd.
Philadelphia, PA 19104 - 215-590-6359
Expertise
- CLINICAL:
Pediatric oncology
Clinical pharmacology
Relapsed pediatric malignancies
- ITMAT:
Dr. Adamson's laboratory focuses on the clinical pharmacology of new drugs for childhood cancer.
- RESEARCH:
My primary research focus has been on pediatric cancer drug development, specifically early phase clinical trails and clinical pharmacologic studies. Until 2008 I served as Chair of the Children's Oncology Group (COG) Developmental Therapeutics Programs and Principal Investigator of the COG Phase 1 Consortium, and in 2011 became Chair of the Children's Oncology Group. Prior to becoming the Director of the Office for Clinical and Translational Research at CHOP, I was the Program Director of the General Clinical Research Center (GCRC) and Principal Investigator of its NICHD funded Pediatric Pharmacology Research Unit (PPRU). My laboratory focuses on the clinical pharmacology of new drugs for childhood cancer using an integrated approach that incorporates preclinical studies in both in vitro and animal models, and clinical trials with clinical pharmacokinetic-pharmacodynamic-pharmacogenetic studies in pediatric patients. As Director of the Office for Clinical and Translational Research at CHOP, I work with clinical and translational investigators in identifying scientific opportunities and in forging productive collaborations throughout CHOP and the University of Pennsylvania.
Appointments
- Professor of Pediatrics in Pharmacology, University of Pennsylvania School of Medicine (2009 – present)
- Professor of Pediatrics at the Children's Hospital of Philadelphia (2006 – present)
- Associate Professor of Pharmacology, University of Pennsylvania School of Medicine (2004 – 2009)
- Associate Professor of Pediatrics at the Children's Hospital of Philadelphia (1999 – 2006)
Education
- M.D., Medicine, Cornell University Medical College, New York, NY (1984)
- B.A., Chemistry, Wesleyan University, Middletown, CT (1980)
Extended Bio
Creating disease-targeted therapies for children with cancer requires a better pathway for moving from the bench to the bedside.
As the recently selected chair of the Children's Oncology Group (COG), a group of more 200 centers that brings together 5,000 international experts in childhood cancer, I am in constant contact with leading researchers across the country. There are great opportunities ahead to improve the outcome for children with cancer, and we are hard at work trying to speed the timeline so the most promising new therapies can move forward. We are working on creating better pathways for disease-targeted therapies for children with cancer, and are focusing our efforts on transforming how new discoveries can move from the bench to the bedside, a process called translational research.
For more than eight years I led a group of 21 institutions that performed the initial evaluation of new drugs for children with cancer. We conducted more than 25 Phase I studies; these studies are the first clinical trials of new anticancer drugs in children whose cancer has recurred despite best-known treatments. I thus have direct knowledge of the investigational new drug trials being conducted not only at Children's Hospital, but at centers worldwide. This allows me to serve as a resource on experimental cancer treatment for Children's Hospital clinicians. For the child whose cancer has recurred, these are the kinds of trials they often seek out.
Even though we have come a long way in our ability to cure children with many types of cancer, we must still strive to find cures for all children. We also must develop treatments that have fewer side effects. Together with the COG, doctors at Children's Hospital are helping to lead the way in this effort.
Publications
- Widemann Brigitte C, Balis Frank M, Kim AeRang, Boron Matthew, Jayaprakash Nalini, Shalabi Aiman, O'Brien Michelle, Eby Michelle, Cole Diane E, Murphy Robert F, Fox Elizabeth, Ivy Percy, Adamson Peter C. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Vol 28(25) . 2010 Sep:3979-86.
